Health state values for use in the economic evaluation of treatments for alzheimers disease

Drugs and Aging

Volumn 29, Issue 1, 2012, Pages 31-43

  Shearer, James ^a   Green, Colin ^a   Ritchie, Craig W ^b   Zajicek, John P ^c  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

Alzheimers disease; Cost utility; Elderly; Quality of life; Utility measurement

Indexed keywords

NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CAREGIVER BURDEN; COGNITION; COMMUNITY CARE; COST UTILITY ANALYSIS; DAILY LIFE ACTIVITY; DECISION MAKING; DISEASE SEVERITY; EQ 5D MEASURE; FULL TIME CARE; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH STATE VALUE; HEALTH STATUS; HEALTH UTILITY INDEX MARK 2; HEALTH UTILITY INDEX MARK 3; HUMAN; INSTITUTIONAL CARE; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; QUALITY OF WELL BEING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; COSTS AND COST ANALYSIS; HEALTH; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84255190986     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11597380-000000000-00000     Document Type: Review

References (68)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366 (9503): 2112-7 (Pubitemid 41797645)
2. Fratiglioni L, de Ronchi D, Agueros-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 1999; 15 (11): 365-75 (Pubitemid 29527871)
3. Luengo-Fernandez R, Leal J, Gray A. Dementia 2010: the economic burden of dementia and associated research funding in the United Kingdom. Oxford: Health Economics Research Centre, University of Oxford for the Alzheimers Research Trust, 2010
4. Meek P, McKeithan K, Schumock G. Economic considerations in Alzheimers disease. Pharmacotherapy 1998; 18 (2): 68-73
5. Alzheimers Association. 2011 Alzheimers disease facts and figures. Alzheimers Dement 2011; 7 (2): 208-44
6. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006 Apr 19; (2): CD003154
7. Birks J. Cholinesterase inhibitors for Alzheimers disease. Cochrane Database Syst Rev 2006 Jan 25; (1): CD005593
8. Green C, Shearer J, Ritchie C, et al. Model-based economic evaluation in Alzheimers disease: a review of the methods available to model Alzheimers disease progression. Value Health 2011; 14 (5): 621-30
9. Mauskopf J, Racketa J, Sherrill E. Alzheimers disease: the strength of association of costs with different measures of disease severity. J Nutr Health Aging 2010; 14 (8): 655-63
10. Riepe M, Mittendorf T, Förstl H, et al. Quality of life as an outcome in Alzheimers disease and other dementias: obstacles and goals. BMC Neurol 2009; 9 (47): 1-8
11. Brazier J, Ratcliffe J, Salomon J, et al. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press, 2007
12. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE, 2008
13. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2006
14. The Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board Stockholm. Sweden: The Pharmaceutical Benefits Board, 2003
15. Foundation for Health Care. Guidelines for pharmacoeconomic research in the Netherlands. Diemen: Foundation for Health Care, 2006
16. Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Barton (ACT): Australian Government Department of Health and Ageing, 2008
17. Neumann PJ, Kuntz KM, Leon J, et al. Health utilities in Alzheimers disease: a cross-sectional study of patients and caregivers. Med Care 1999; 37 (1): 27-32
18. Ward A, Caro J, Getsios D, et al. Assessment of health economics in Alzheimers disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 2003; 18 (8): 740-7 (Pubitemid 37009757)
19. Coucill W, Bryan S, Bentham P, et al. EQ-5D in patients with dementia: an investigation of inter-rater agreement. Med Care 2001; 39 (8): 760-71 (Pubitemid 33686260)
20. Andersen C, Wittrup-Jensen K, Lolk A, et al. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes 2004; 2 (1): 52
21. Dixon S, Walker M, Salek S. Incorporating carer effects into economic evaluation. Pharmacoeconomics 2006; 24 (1): 43-53 (Pubitemid 43197230)
22. Ló pez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, et al. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Neurology 2006; 67 (12): 2186-91
23. Jönsson L, Andreasen N, Kilander L, et al. Patient- and proxy-reported utility in Alzheimer disease using the EuroQol. Alzheimer Dis Assoc Disord 2006; 20 (1): 49-55.
24. Naglie G, Tomlinson G, Tansey C, et al. Utility-based quality of life measures in Alzheimers disease. Qual Life Res 2006; 15 (4): 631-43 (Pubitemid 43843971)
25. Miller E, Schneider L, Zbrozek A, et al. Sociodemographic and clinical correlates of utility scores in Alzheimers disease. Value Health 2008; 11 (7): 1120-30
26. Karlawish J, Zbrozek A, Kinosian B, et al. Preference-based quality of life in patients with Alzheimers disease. Alzheimers Dement 2008; 4 (3): 193-202 (Pubitemid 351682259)
27. Karlawish J, Zbrozek A, Kinosian B, et al. Caregivers assessments of preference-based quality of life in Alzheimers disease. Alzheimers Dement 2008; 4 (3): 203-11 (Pubitemid 351682260)
28. Mesterton J, Wimo A, By A, et al. Cross sectional observational study on the societal costs of Alzheimers disease. Curr Alzheimer Res 2010; 7 (4): 358-67
29. Bhattacharya S, Vogel A, Hansen M, et al. Generic and disease-specific measures of quality of life in patients with mild Alzheimers disease. Dement Geriatr Cogn Disord 2010; 30 (4): 327-33
30. Kunz S. Psychometric properties of the EQ-5D in a study of people with mild to moderate dementia. Qual Life Res 2010; 19 (3): 425-34
31. Brooks R, Group TE. EuroQol: the current state of play. Health Policy 1996; 37 (1): 53-72 (Pubitemid 26191458)
32. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35 (11): 1095-108 (Pubitemid 127453463)
33. Ankri J, Beaufils B, Novella JL, et al. Use of the EQ-5D among patients suffering from dementia. J Clin Epidemiol 2003; 56 (11): 1055-63 (Pubitemid 37386332)
34. Feeny D, Furlong W, Torrance G, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002; 40 (2): 113-28
35. Torrance G, Feeny D, Furlong W, et al. Multi-attribute preference functions for a comprehensive health status classification systems: health utilities index mark 2. Med Care 1996; 34 (7): 702-22 (Pubitemid 126433265)
36. Asakawa K, Rolfson D, Senthilselvan A, et al. Health utilities index mark 3 showed valid in Alzheimer disease, arthritis, and cataracts. J Clin Epidemiol 2008; 61 (7): 733-9
37. Kaplan R, Bush J, Berry C. Health status: types of validity and the index of well-being. Health Serv Res 1976; 11 (4): 478-507 (Pubitemid 8111230)
38. Kerner D, Patterson T, Grant I, et al. Validity of the Quality of Well-Being Scale for patients with Alzheimers disease. J Aging Health 1998; 10 (1): 44-61
39. Serrano-Aguilar P, Lopez-Bastida J, Yanes-Lopez V. Impact on health-related quality of life and perceived burden of informal caregivers of individuals with Alzheimers disease. Neuroepidemiology 2006; 27 (3): 136-42 (Pubitemid 44651433)
40. Jönsson L, Jönhagen ME, Kilander L, et al. Determinants of costs of care for patients with Alzheimers disease. Int J Geriatr Psychiatry 2006; 21 (5): 449-59.
41. McLaughlin T, Feldman H, Fillit H, et al. Dependence as a unifying construct in defining Alzheimers disease severity. Alzheimers Dement 2010; 6 (6): 482-93
42. Murman DL, Colenda CC. The economic impact of neuropsychiatric symptoms in Alzheimers disease: can drugs ease the burden? Pharmacoeconomics 2005; 23 (3): 227-42 (Pubitemid 40663630)
43. Neumann PJ. Health utilities in Alzheimers disease and implications for cost-effectiveness analysis. Pharmacoeconomics 2005; 23 (6): 537-41 (Pubitemid 40994123)
44. Ló pez-Bastida J, Hart W, Garcia-Perez L, et al. Costeffectiveness of donepezil in the treatment of mild or moderate Alzheimers disease. J Alzheimers Dis 2009; 16 (2): 399-407
45. Kirbach S, Simpson K, Nietert P, et al. A Markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimers disease. Clin Drug Investig 2008; 28 (5): 291-303 (Pubitemid 351521382)
46. Murman DL, Chen Q, Powell MC, et al. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002 Dec 10; 59 (11): 1721-9 (Pubitemid 35424453)
47. Fuh J-L, Wang S-J. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimers disease in Taiwan. Int J Geriatr Psychiatry 2008; 23 (1): 73-8 (Pubitemid 351181609)
48. Teipel S, EwersM, Reisig V, et al. Long-term cost-effectiveness of donepezil for the treatment of Alzheimers disease. Eur Arch Psychiatry Clin Neurosci 2007; 257 (6): 330-6 (Pubitemid 47485284)
49. Getsios D, Migliaccio-Walle K, Caro J. NICE costeffectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? Pharmacoeconomics 2007; 25 (12): 997-1006 (Pubitemid 350208905)
50. Green C, Picot J, Lovemen E, et al. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimers disease. Pharmacoeconomics 2005; 23 (12): 1271-82 (Pubitemid 41803322)
51. Weycker D, Taneja C, Edelsberg J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimers disease patients receiving donepezil. Curr Med Res Opin 2007; 23 (5): 1187-97 (Pubitemid 46799603)
52. Gagnon M, Rive B, Hux M, et al. Cost-effectiveness of memantine compared with standard care in moderate-tosevere Alzheimer disease in Canada. Can J Psychiatry 2007; 52 (8): 519-26 (Pubitemid 47403186)
53. Sapin C, Livingston G, Katona C. Main factors influencing preference-based utility values in Alzheimers disease: results from the LASER-AD study [abstract]. 7th International Conference on Alzheimers and Parkinsons Disease; 2005 Mar 9-13; Sorrento
54. Jönsson L. Cost-effectiveness of memantine for moderate to severe Alzheimers disease in Sweden. Am J Geriatr Pharmacother 2005; 3 (2): 77-86. (Pubitemid 41200509)
55. Caro J, Salas M, Ward A, et al. Assessing the health and economic impact of galantamine treatment in patients with Alzheimers disease in the health care systems of different countries. Drugs Aging 2004; 21 (10): 677-86 (Pubitemid 39128000)
56. Martikainen J, Valtonen H, PirttiläT. Potential costeffectiveness of a family-based program in mild Alzheimers disease patients. Eur J Health Econ 2004; 5 (2): 136-42 (Pubitemid 38832956)
57. Jones R, McCrone P, Guillhaume C. Cost effectiveness of memantine in Alzheimers disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004; 21 (9): 607-20 (Pubitemid 39070995)
58. McMahon P, Araki S, Neumann P, et al. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 2003; 228 (2): 515-22 (Pubitemid 36910096)
59. Kulasingam S, Samsa G, Zarin D, et al. When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimers dementia? A decision analysis. Value Health 2003; 6 (5): 542-50 (Pubitemid 37187716)
60. Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimers disease in Japan. Dement Geriatr Cogn Disord 2002; 13 (1): 33-9 (Pubitemid 33153186)
61. Ikeda S, Niwata S, Igarashi Y. Evaluating QOL of elderly people with dementia (in Japanese). Jpn J Pharmacoepidemiol 2001; 5 (1): 99-105
62. McMahon P, Araki S, Neumann P, et al. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology 2000; 217 (1): 58-68 (Pubitemid 33097579)
63. Neumann PJ, Hermann RC, Kuntz KM, et al. Costeffectiveness of donepezil in the treatment of mild or moderate Alzheimers disease. Neurology 1999; 52 (6): 1138-45 (Pubitemid 29177912)
64. Cohen J, Neumann P. Decision analytic models for Alzheimers disease: state of the art and future directions. Alzheimers Dement 2008; 4 (3): 212-22 (Pubitemid 351682261)
65. Logsdon R, Gibbons L, McCurry S, et al. Quality of life in Alzheimers disease: patient and caregiver reports. J Ment Health Aging 1999; 5 (1): 21-32 (Pubitemid 29235115)
66. Rabins P, Kasper J, Kleinman L, et al. Concepts and methods in the development of the ADRQL: an instrument for assessing health-related quality of life in persons with Alzheimers disease. J Ment Health Aging 1999; 5 (1): 33-48 (Pubitemid 29235116)
67. Brazier J, Tsuchiya A. Preference-based condition-specific measures of health: what happens to cross programme comparability? Health Econ 2010; 19 (2): 125-9
68. Iliffe S, Curry L, Kharicha K, et al. Developing a Dementia Research Registry: a descriptive case study from North Thames DeNDRoN and the EVIDEM programme. BMC Med Res Methodol 2011; 11 (1): 9